Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases

CardioVascular and Interventional Radiology

Volumn 35, Issue 5, 2012, Pages 1066-1073

  Seidensticker, Ricarda ^a   Denecke, Timm ^b   Kraus, Patrick ^a   Seidensticker, Max ^a   Mohnike, Konrad ^a   Fahlke, Jörg ^a   Kettner, Erika ^c   Hildebrandt, Bert ^b   Dudeck, Oliver ^a   Pech, MacIej ^a   Amthauer, Holger ^a   Ricke, Jens ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Schwerpunktpraxis für Haematologie und Onkologie Hasselbachplatz   (Germany)

Author keywords

Colorectal cancer; Liver metastases; Radioembolization; Salvage therapy; Yttrium 90

Indexed keywords

ALKALINE PHOSPHATASE; CARCINOEMBRYONIC ANTIGEN; MACROSALB TC 99M; MICROSPHERE Y 90; RADIOACTIVE MICROSPHERE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; BEST SUPPORTIVE CARE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; FATIGUE; FEMALE; GERMANY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVER DISEASE; LIVER METASTASIS; MALE; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOEMBOLIZATION; RADIOEMBOLIZATION INDUCED LIVER DISEASE; SIDE EFFECT; TUMOR VOLUME;

COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84867532049     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-011-0234-7     Document Type: Article

References (29)

1. Europe against Colorectal Cancer Declaration of Brussels 9 May 2007. http://www.future-health-2007.com/fileadmin/user-upload/Brussels-Declaration. pdf. Accessed July 2009
2. Lepage C, Remontet L, Launoy G et al (2008) French network of cancer registries (FRANCIM). Trends in incidence of digestive cancers in France. Eur J Cancer Prev 17:13-17
3. Manfredi S, Lepage C, Hatem C et al (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244:254-259
4. Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP (2007) Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 8:898-911
5. Folprecht G, Grothey A, Alberts S et al (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16:1311-1319
6. Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007-1016
7. Grothey A, Sugrue MM, Purdie DM et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BriTE). J Clin Oncol 26:5326-5334
8. Tol J, Koopman M, Cats A et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563-572
9. Gervais DA, Goldberg SN, Brown DB et al (2009) Society of interventional radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol 20(7 Suppl):S342-S347
10. Popescu I, Alexandrescu S, Croitoru A, Boros M (2009) Strategies to convert to resectability the initially unresectable colorectal liver metastases. Hepatogastroenterology 56:739-744
11. Ricke J, Wust P, Wieners G et al (2005) Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavourable lesions for thermal ablation. J Vasc Interv Radiol 15:1279-1286
12. Denecke T, Lopez, Hänninen E (2008) Brachytherapy of liver metastases. Recent Results Cancer Res 177:95-104
13. 90Y microsphere brachytherapy for unresectable colorectal metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65:412-425
14. Cosimelli M, Golfieri R, Cagol PP et al (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103:324-331
15. Jakobs TF, Hoffmann RT, Dehm K et al (2008) Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol 19:1187-1195
16. Hoffmann RT, Jakobs TF, Kubisch C et al (2010) Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver disease-is it feasible? Eur J Radiol 74:199-205
17. Van den Eynde M, Flamen P, El Nakadi I et al (2008) Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. Clin Nucl Med 33:697-699
18. Denecke T, Rühl R, Hildebrandt B et al (2008) Planning transarterial radioembolization of colorectal liver metastases with Yttrium 90 microspheres: evaluation of a sequential diagnostic approach using radiologic and nuclear medicine imaging techniques. Eur Radiol 18:892-902
19. Saltz L, Meropol N, Loehrer P et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208
20. Sangro B, Gil-Alzugaray B, Rodriguez J et al (2008) Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112:1538-1546
21. Hendlisz A, Van den Eynde M, Peeters M et al (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28:3687-3694
22. Dawood O, Mahadevan A, Goodman KA (2009) Stereotactic body radiation therapy for liver metastases. Eur J Cancer 45:2947-2959
23. Jonker DJ, O'Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048
24. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664
25. van Hazel G, Blackwell A, Anderson J et al (2004) Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88:78-85
26. Sharma R, van Hazel G, Morgan B et al (2007) Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 25:1099-1106
27. van Hazel GA, Pavlakis N, Goldstein D et al (2009) Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using Yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 27:4089-4095
28. Kuebler JP (2009) Radioembolization of liver metastases in patients with colorectal cancer: A nonsurgical treatment with combined modality potential. J Clin Oncol 27:4041-4042
29. Rose SC, Gulec SA (2009) Yttrium 90 radiomicrosphere therapy: ongoing clinical trials. J Interv Oncol 2:72-83